Patents by Inventor Peter J. Schatz

Peter J. Schatz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8729030
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: May 20, 2014
    Assignee: Affymax, Inc.
    Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Palani Balu, Genet Zemede
  • Publication number: 20130244939
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: November 1, 2012
    Publication date: September 19, 2013
    Applicant: AFFYMAX, INC.
    Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
  • Publication number: 20130012685
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: July 3, 2012
    Publication date: January 10, 2013
    Applicant: AFFYMAX, INC.
    Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, Yaohua S. Dong, David Tumelty, Guy Lalonde, Brian T. Frederick, Anjan Chakrabarti, Palani Balu, Peter J. Schatz, Nicholas C. Wrighton, William J. Dower
  • Patent number: 8304391
    Abstract: Peptide compounds that are agonists of the erythropoietin receptor (EPO-R) are described, as well as therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Grant
    Filed: March 17, 2009
    Date of Patent: November 6, 2012
    Assignee: Affymax, Inc.
    Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
  • Patent number: 8227422
    Abstract: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: July 24, 2012
    Assignee: Glaxosmithkline LLC
    Inventors: William J. Dower, Ronald W. Barrett, Steven E. Cwirla, David J. Duffin, Christian M. Gates, Sherril S. Haselden, Larry C. Mattheakis, Peter J. Schatz, Christopher R. Wagstrom, Nicholas C. Wrighton
  • Publication number: 20120157660
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: August 18, 2010
    Publication date: June 21, 2012
    Applicant: AFFYMAX, INC.
    Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, David Tumelty, Guy Lalonde, Palani Balu, Peter J. Schatz, William J. Dower, Anjan Chakrabarti, Yaohua S. Dong, Brian T. Frederick, Nicholas C. Wrighton
  • Publication number: 20110282029
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: December 10, 2010
    Publication date: November 17, 2011
    Applicant: AFFYMAX, INC.
    Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, Yaohua S. Dong, David Tumelty, Guy Lalonde, Brian T. Frederick, Anjan Chakrabarti, Palani Balu, Peter J. Schatz, Nicholas C. Wrighton, William J. Dower
  • Publication number: 20110245176
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: November 12, 2010
    Publication date: October 6, 2011
    Applicant: AFFYMAX, INC.
    Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
  • Patent number: 7855175
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: December 21, 2010
    Assignee: Affymax, Inc.
    Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Palani Balu, Genet Zemede
  • Publication number: 20090227508
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: March 17, 2009
    Publication date: September 10, 2009
    Applicant: Affymax, Inc.
    Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
  • Publication number: 20090214489
    Abstract: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.
    Type: Application
    Filed: April 15, 2008
    Publication date: August 27, 2009
    Inventors: William J. Dower, Ronald W. Barrett, Steven E. Cwirla, David J. Duffin, Christian M. Gates, Sherril S. Haselden, Larry C. Mattheakis, Peter J. Schatz, Christopher R. Wagstrom, Nicholas C. Wrighton
  • Publication number: 20090209457
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat or to prevent anti-erythropoietin (EPO) antibody-mediated disorders such as pure red cell aplasia (PRCA) that are characterized by anti-EPO antibodies. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: February 13, 2009
    Publication date: August 20, 2009
    Applicant: Affymax, Inc.
    Inventors: Anne-Marie Duliege, Peter J. Schatz, Richard Stead, Kathryn Wynne Woodburn
  • Publication number: 20090131317
    Abstract: The present invention relates to peptides and compounds that bind to a TRAIL receptor or otherwise act as a TRAIL receptor agonist, as well as methods of treating human diseases using the same. In addition, methods of synthesizing the peptides and compounds described herein are provided by the present invention.
    Type: Application
    Filed: June 23, 2008
    Publication date: May 21, 2009
    Applicant: AFFYMAX, INC.
    Inventors: Yvonne M. Angell, Ashok Bhandari, Jennifer Green, Peter J. Schatz, Christopher P. Holmes
  • Patent number: 7528104
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Grant
    Filed: May 12, 2004
    Date of Patent: May 5, 2009
    Assignee: Affymax, Inc.
    Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
  • Publication number: 20090048166
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: July 11, 2008
    Publication date: February 19, 2009
    Applicant: AFFYMAX, INC.
    Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
  • Publication number: 20090005292
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: November 11, 2005
    Publication date: January 1, 2009
    Applicant: AFFYMAX, INC.
    Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, David Tumelty, Guy Lalonde, Palani Balu, Peter J. Schatz, William J. Dower, Anjan Chakrabarti, Yaohua S. Dong, Brian T. Frederick, Nicholas C. Wrighton
  • Patent number: 7414105
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Grant
    Filed: October 27, 2005
    Date of Patent: August 19, 2008
    Assignee: Affymax, Inc.
    Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
  • Publication number: 20080108564
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: April 13, 2007
    Publication date: May 8, 2008
    Applicant: Affymax, Inc.
    Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, Yaohua S. Dong, David Tumelty, Guy Lalonde, Brian T. Frederick, Anjan Chakrabarti, Palani Balu, Peter J. Schatz, Nicholas C. Wrighton, William J. Dower
  • Patent number: 7091311
    Abstract: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.
    Type: Grant
    Filed: February 27, 2002
    Date of Patent: August 15, 2006
    Assignee: SmithKline Beecham Corporation
    Inventors: William J. Dower, Ronald W. Barrett, Steven E. Cwirla, David J. Duffin, Christian M. Gates, Sherril S. Haselden, Larry C. Mattheakis, Peter J. Schatz, Christopher R. Wagstrom, Nicholas C. Wrighton
  • Patent number: 7084245
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Grant
    Filed: May 12, 2004
    Date of Patent: August 1, 2006
    Assignee: Affymax, Inc.
    Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede